HC Wainwright Analysts Give Inovio Pharmaceuticals, Inc. (NASDAQ:INO) a $13.00 Price Target
HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals, Inc. (NASDAQ:INO) in a report released on Thursday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued research reports about the company. Piper Jaffray Companies raised Inovio Pharmaceuticals from a neutral rating to an overweight rating and set a $14.00 target price on the stock in a report on Thursday, June 8th. Jefferies Group LLC reaffirmed a neutral rating and issued a $38.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. BNP Paribas reaffirmed a neutral rating and issued a $39.00 target price on shares of Inovio Pharmaceuticals in a report on Monday, May 1st. Zacks Investment Research raised Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 target price on the stock in a report on Tuesday, July 11th. Finally, Maxim Group set a $12.00 target price on Inovio Pharmaceuticals and gave the company a buy rating in a report on Thursday, June 8th. Two analysts have rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $19.90.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded up 0.91% during trading on Thursday, reaching $5.57. The company’s stock had a trading volume of 377,028 shares. The firm’s 50-day moving average is $7.52 and its 200 day moving average is $6.90. The company’s market cap is $415.67 million. Inovio Pharmaceuticals has a 52-week low of $5.50 and a 52-week high of $11.00.
Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.31). The firm had revenue of $10.40 million for the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The company’s revenue was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) EPS. On average, equities research analysts predict that Inovio Pharmaceuticals will post ($1.09) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.watchlistnews.com/hc-wainwright-analysts-give-inovio-pharmaceuticals-inc-nasdaqino-a-13-00-price-target/1463824.html.
In other news, Director David B. Weiner sold 8,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total value of $64,000.00. Following the completion of the transaction, the director now directly owns 740,956 shares in the company, valued at approximately $5,927,648. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in INO. Bank of America Corp DE boosted its position in shares of Inovio Pharmaceuticals by 14.6% in the first quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 3,605 shares during the last quarter. American International Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock worth $270,000 after buying an additional 2,695 shares during the last quarter. Private Capital Advisors Inc. purchased a new position in shares of Inovio Pharmaceuticals during the second quarter worth approximately $274,000. Metropolitan Life Insurance Co. NY boosted its position in shares of Inovio Pharmaceuticals by 8.5% in the first quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock worth $341,000 after buying an additional 4,020 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new position in shares of Inovio Pharmaceuticals during the fourth quarter worth approximately $559,000. Institutional investors own 22.90% of the company’s stock.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.